ABSTRACT
BackgroundAs increasing cases of COVID-19 around world, urgent need for effective COVID-19-specific therapeutic drugs is necessary; therefore, we conducted a pilot randomized-controlled study to evaluate the efficacy of 99mTc-MDP for COVID-19 therapeutic treatment. MethodsA total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020, and then were assigned, in a 1:1 ratio, into control (11 patients) and 99mTc-MDP group (10 patients). Patients in the control group received routine treatment and patients assigned to the 99mTc-MDP group received a combination of routine treatment and an administration of 99mTc-MDP injection of 5ml/day. Both of the patients in the control and 99mTc-MDP groups were treated for 7 days with the primary end point of CT-based radiological pulmonary changes during 7-day follow-up. FindingsFrom baseline to the day 7, 8 (80%) of 10 mild patients in the 99mTc-MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung. None of the patients in the 99mTc-MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe. During days 7 through 14, the number of patients with radiological improvement in the 99mTc-MDP group remained consistent, and only 1 additional case (22%) in the control group were reported. ConclusionIn this randomized pilot study, 99mTc-MDP had an effective inhibitory effect on the inflammatory disease progression for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment.
ABSTRACT
Objective To investigate the factors affecting insufficient blood collection from volunteer donors. Methods Volunteer blood donors in our hospital were divided into two groups: group A (volunteer donors from January 2001 to December 2003) and group B (volunteer donors from January to June in 2004) after improving the environment of blood collection and service quality. The cases and main affecting factors of insufficient blood collection were analysed. Results The percentage of cases with insufficient blood collection in group A and group B was 0.95% and 0.53%, respectively, which had a significant difference between the two groups (P
ABSTRACT
0.05).⑵ With the increase of titers of anti-A(B) antibodies of IgG type, both the incidence and severity of HDN elevated (P
ABSTRACT
Objective To analyze the curative effect of blood transfusion on 100 patients undergoing liver transplantation,to efficiently enhance hemostasis and coagulation function of the patients,to lower the incidence of the operative complications,and to put forward the guideline of blood transfusion to the patients undergoing liver transplantation.Methods The volumes of red blood cells concentrates(RCCs),fresh frozen plasma(FFP),cryopreserved platelets,and cryoprecipitate transfused to the patients undergoing liver transplantation were measured before,during and after the operation respectively.The volumes of blood components transfused to the 50 patients in the former stage and 50 patients in the later stage of liver transplantation in our hospital were also measured respectively.Results The mean volume of the blood components transfused to each patient was 3 334ml.The ratios of the transfused blood volumes to 100 patients were 4.3%,53.4% and 42.3% before,during and after operation respectively.The rate of blood components transfusion was 100% and the ratio of transfused blood volumes to the patients between RCCs and FFP was 1.45:1.The mean volumes of the transfused blood and the operative complications of 50 patients in the former stage of liver transplantation of our hospital were significantly higher than those of the 50 patients in the later stage.Conclusion It is very vital in the scientific,safe and reasonable blood transfusion for the success of liver transplantation,which significantly lowers the incidence of operative complications,such as massive haemorrhage during and after operation,and thrombosis at inosculation of liver artery and portal vein.
ABSTRACT
Objective To study the technology of loading trehalose into cytoplasm of human platelets before lyophilization,and to determine the optimal experimental conditions of pretreatment technology.Methods The curves of loading efficiency,the internal trehalose concentration versus incubated time,temperature,and external trehalose concentration were drawn up to screen the optimal loading parameters.Results The loading efficiency was linear to the incubated time(2 hours later) and incubated temperature(range from 30℃ to 40℃),respectively.The loading efficiency almost reached 60 percent when the platelets were incubated at 37℃ for 4h.The intracellular trehalose concentration was increased with the raise of the external trehalose concentration(
ABSTRACT
0.01).After incubation with trehalose for 4h,the expression of CD62p increased,and it decreased when platelets activation inhibitor PGE-1 and adenosine were added to the incubation buffer.The expression of PAC-1 showed no difference among the three groups. Conclusion The preprocessing before platelets lyophilization has no significant effects on the function and activity of platelets when the platelets activation inhibitor is added.
